Clinical trials: Relapsing-Remitting MS
Relapsing Remitting Multiple Sclerosis
Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)
The investigators hypothesize that Mycobacterium avium paratuberculosis positive Relapsing Remitting MS subjects will have a greater response to Interferon beta-1a therapy plus RHB-104 than from Interferon beta-1a alone.
- Trial name
- CEASE-MS (NCT01717664)
- Testing
- RHB-104
- Where
- 2 sites in Israel
- Volunteers
- 18 people
- Sponsor
- RedHill Biopharma Limited
Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.
- Trial name
- MS (NCT06800404)
- Testing
- Autologous HB-adMSCs
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hope Biosciences Research Foundation
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
The goal of this observational study is to validate a novel, cost-effective method for real-world assessment using patient-acquired "selfie" videos in people with multiple sclerosis.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, MS (Multiple Sclerosis)
- Trial name
- NCT07222618
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse…
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT05663853
- Where
- 4 sites in United States
- Volunteers
- 137 people
- Sponsor
- LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-Remitting
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
The purpose of this study is to determine whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms whether…
- Trial name
- NCT00099502
- Testing
- Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone
- Where
- 199 sites in United States, Argentina and 24 more
- Volunteers
- 2,244 people
- Sponsor
- Bayer
Multiple Sclerosis
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- FREEDOMS II (NCT00355134)
- Testing
- Fingolimod
- Where
- 112 sites in United States, Australia and 6 more
- Volunteers
- 1,083 people
- Sponsor
- Novartis
Relapsing Remitting Multiple Sclerosis
A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS
To establish a pharmacokinetic (PK) profile of BG00012, as measured by its primary metabolite, monomethyl fumarate (MMF), during a 24-hour dosing period in subjects with relapsing-remitting multiple sclerosis (RRMS), with a…
- Trial name
- NCT00837785
- Testing
- BG00012
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Biogen
Multiple Sclerosis (MS) - Relapsing-remitting
Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.
REDEFINE-MS is a research study for people with relapsing multiple sclerosis (MS) who are participating in the RESHAPE-MS trial.
- Trial name
- REDIFINE MS (NCT07758270)
- Testing
- Remibrutinib, Ocrelizumab (US)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Multiple Sclerosis
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.
- Trial name
- START (NCT01585298)
- Testing
- FTY720
- Where
- 258 sites in Germany
- Volunteers
- 6,998 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
The primary objective of the study is to evaluate the adherence to the treatment with interferon beta-1b, in patients diagnosed with isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or secondary progressive…
- Trial name
- ADHERENCE (NCT03408093)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Volunteers
- 120 people
- Sponsor
- Bayer
Relapsing-remitting Multiple Sclerosis
Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS
Between 15-20% of MS patients decide not to initiate disease modifying therapies after being diagnosed with MS. For this study, we will develop a telephone-based talk therapy intervention and then conduct a randomized controlled…
- Trial name
- MIMS (NCT02010554)
- Testing
- Brief Education, Motivational Interviewing-Cognitive Behavioral Therapy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Missouri, Kansas City
Multiple Sclerosis
Depression and Fatigue in MS Patients Treated With Betaferon.
This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.
- Trial name
- FADO (NCT01354665)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046)
- Where
- Poland
- Volunteers
- 567 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS
The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis (MS).
- Trial name
- CHANGE-MS (NCT02782858)
- Testing
- GNbAC1
- Where
- 12 sites in Bulgaria, Croatia and 10 more
- Volunteers
- 270 people
- Sponsor
- GeNeuro SA
Multiple Sclerosis
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
- Trial name
- NCT00035529
- Testing
- BMS 188667 (Abatacept)
- Where
- 10 sites in United States
- Sponsor
- Bristol-Myers Squibb
Relapsing Remitting Multiple Sclerosis, Clinically Isolated Syndrome
Clinical Importance of Glucose Regulation in Relapsing MS
The purpose of this study is to assess the relationship of blood glucose levels in persons with Multiple Sclerosis (MS) who have experienced a relapse and will be receiving intravenous steroids for the relapse, to their recovery…
- Trial name
- NCT03004079
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Virginia
Multiple Sclerosis, Relapsing-Remitting
A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis
The purpose of this study is to investigate the safety of subcutaneous (SC) interferon beta therapies with regard to frequency of injection site reactions (ISR) and flu-like symptoms (FLS) as reported by the relapsing-remitting…
- Trial name
- PERFECT (NCT03347370)
- Testing
- SC Peginterferon beta-1a, SC interferon beta-1a, SC interferon beta-1b
- Where
- Germany
- Volunteers
- 626 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Impact of Vitamin A on Multiple Sclerosis (MS)
The aim of this study is the comparison between the effects of supplementation with 25000 IU preformed vitamin A (retinyl palmitate) or placebo for first 6 months and 10000 IU/day for next 6 months on disease activity and…
- Trial name
- MS (NCT01417273)
- Testing
- vitamin A
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Tehran University of Medical Sciences
Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS)
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
This project is to: 1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients. 2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period. 3.
- Conditions
- Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS), Secondary-progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- INsIDER (NCT05177523)
- Testing
- MRI, Neurocognitive examination for healthy subjects, blood sampling
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Relapsing-Remitting Multiple Sclerosis
Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects
Brief Summary: 800 RRMS Subjects currently treated with Avonex or Copaxone will be randomized to either continue on their current therapy or receive Rebif therapy. The subjects will be followed for 2 years.
- Trial name
- NCT00101959
- Testing
- Rebif
- Sponsor
- EMD Serono